Arabic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Dexmedetomidine Combined With Lidocaine Infusion Affect Inflammation Cytokines

يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
يتم حفظ الارتباط في الحافظة
الحالةتجنيد
الرعاة
Anqing Municipal Hospital
المتعاونون
The First Affiliated Hospital of Anhui Medical University

الكلمات الدالة

نبذة مختصرة

Objective: The present study was to evaluate the effects of dexmedetomidine alone, lidocaine alone and their combined infusion on postoperative inflammation cytokines after Laparoscopic hysterectomy.
Methods: Investigators enrolled 160 women with American Society of Anesthesiologists (ASA) physical status I and II, aged 40-65 years, and scheduled for elective laparoscopic hysterectomy with general anesthesia from October 2017 to August 2018. The participants were randomly assigned into four groups(n=40 each group): group CON received normal saline infusion, group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion), group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) and group LIDO+DEX received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusions (0.5 µg/kg loading, 0.4 µg/kg/h infusion). The four groups received an IV bolus infusion of normal saline, lidocaine, dexmedetomidine and lidocaine combined with dexmedetomidine respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of normal saline, lidocaine, dexmedetomidine and lidocaine combined with dexmedetomidine until abdominal wound closure, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), the end of surgery (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4).

تواريخ

آخر التحقق: 01/31/2020
تم الإرسال لأول مرة: 08/22/2017
تم إرسال التسجيل المقدر: 09/05/2017
أول نشر: 09/07/2017
تم إرسال آخر تحديث: 02/16/2020
آخر تحديث تم نشره: 02/18/2020
تاريخ بدء الدراسة الفعلي: 10/31/2017
تاريخ الإنجاز الأساسي المقدر: 02/17/2020
التاريخ المتوقع لانتهاء الدراسة: 02/19/2020

حالة أو مرض

Anesthesia; Reaction

التدخل / العلاج

Drug: Saline

Drug: Lidocaine

Drug: Dexmedetomidine

Drug: Lidocaine plus Dexmedetomidine

مرحلة

-

مجموعات الذراع

ذراعالتدخل / العلاج
Experimental: Intravenous saline, dexmedetomidine and lidocaine
Experimental: Intravenous saline, dexmedetomidine, lidocaine and combination
Experimental: Intravenous saline,dexmedetomidine plus lidocaine
Experimental: Intravenous saline, dexmedetomidine combined with lidocaine

معايير الأهلية

الأعمار المؤهلة للدراسة 40 Years إلى 40 Years
الأجناس المؤهلة للدراسةFemale
يقبل المتطوعين الأصحاءنعم
المعايير

Inclusion Criteria:

- American Society of Anesthesiologists (ASA) physical status I and II

- weighted 50 kg-65 kg

- aged 40-65 yr

- elective laparoscopic hysterectomy with general anesthesia

Exclusion Criteria:

- a history of allergy to local anesthetics

- severe respiratory, renal or hepatic disease

- preoperative opioids medication

- psychiatric medical history

- Patients with severe hypotension [mean arterial pressure (MAP<60 mmHg)] or bradycardia [heart rate (HR) <40 beats per minute (bpm)], arrhythmia, or urticaria due to lidocaine and dexmedetomidine infusion during the surgery

النتيجة

مقاييس النتائج الأولية

1. Interleukin-6 [postoperative 24 hours]

Interleukin-6 level in serum was measured at the before administration of drugs (T1), Interleukin-6 level in serum was measured at the end of the operation (T2); Interleukin-6 level in serum was measured at the postoperative 2 hour (T3); Interleukin-6 level in serum was measured at the postoperative 24 hour (T4)

2. Tumor necrosis factor-α [postoperative 24 hours]

Tumor necrosis factor-α level in serum was measured at the before administration of drugs (T1); Tumor necrosis factor-α level in serum was measured at the end of the operation (T2); Tumor necrosis factor-α level in serum was measured at the postoperative 2 hour (T3); Tumor necrosis factor-α level in serum was measured at the postoperative 24 hour (T4)

3. Interleukin-1 [postoperative 24 hours]

Interleukin-1 level in serum was measured at the before administration of drugs (T1); Interleukin-1 level in serum was measured at the end of the operation (T2); Interleukin-1 level in serum was measured at the postoperative 2 hour (T3); Interleukin-1 level in serum was measured at the postoperative 24 hour (T4)

انضم إلى صفحتنا على الفيسبوك

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم

  • يعمل في 55 لغة
  • العلاجات العشبية مدعومة بالعلم
  • التعرف على الأعشاب بالصورة
  • خريطة GPS تفاعلية - ضع علامة على الأعشاب في الموقع (قريبًا)
  • اقرأ المنشورات العلمية المتعلقة ببحثك
  • البحث عن الأعشاب الطبية من آثارها
  • نظّم اهتماماتك وابقَ على اطلاع دائم بأبحاث الأخبار والتجارب السريرية وبراءات الاختراع

اكتب أحد الأعراض أو المرض واقرأ عن الأعشاب التي قد تساعد ، واكتب عشبًا واطلع على الأمراض والأعراض التي تستخدم ضدها.
* تستند جميع المعلومات إلى البحوث العلمية المنشورة

Google Play badgeApp Store badge